Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

Updated pharmacodynamic and safety data from SUNFISH Part 1, a study evaluating the oral SMN2 splicing modifier RG7916 in patients with Type 2 or 3 spinal muscular atrophy (P4.453)

Eugenio Mercuri, Giovanni Baranello, Jan Kirschner, Laurent Servais, Nathalie Goemans, Maria Carmela Pera, Anne Marquet, Gillian Armstrong, Heidemarie Kletzl, Marianne Gerber, Christian Czech, Yumi Cleary, Margaret Chan, Stephan Nave, Ksenija Gorni, Omar Khwaja
First published April 9, 2018,
Eugenio Mercuri
1Catholic University and Policlinico Gemelli Roma Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Baranello
2Carlo Besta Neurological Research Institute Foundation Milan Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Kirschner
3Medical Center-University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Servais
4Institute of Myology Paris France
5Centre Hospitalier Régional de La Citadelle Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Goemans
6University Hospitals Leuven Leuven Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Carmela Pera
1Catholic University and Policlinico Gemelli Roma Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Marquet
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gillian Armstrong
8Roche Products Ltd Welwyn Garden City United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidemarie Kletzl
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Gerber
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Czech
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yumi Cleary
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Chan
9Roche Innovation Center New York New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Nave
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ksenija Gorni
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar Khwaja
7Roche Innovation Center Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Updated pharmacodynamic and safety data from SUNFISH Part 1, a study evaluating the oral SMN2 splicing modifier RG7916 in patients with Type 2 or 3 spinal muscular atrophy (P4.453)
Eugenio Mercuri, Giovanni Baranello, Jan Kirschner, Laurent Servais, Nathalie Goemans, Maria Carmela Pera, Anne Marquet, Gillian Armstrong, Heidemarie Kletzl, Marianne Gerber, Christian Czech, Yumi Cleary, Margaret Chan, Stephan Nave, Ksenija Gorni, Omar Khwaja
Neurology Apr 2018, 90 (15 Supplement) P4.453;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: SUNFISH (NCT02908685) study assesses the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of RG7916 in patients with Type 2 or Type 3 spinal muscular atrophy (SMA).

Background: SMA is characterized by motor neuron loss and muscle atrophy due to reduced levels of survival of motor neuron (SMN) protein. RG7916 is an orally administered, centrally and peripherally distributed small molecule that modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA and increases SMN protein levels.

Design/Methods: SUNFISH is a multicenter, double-blind, placebo-controlled trial (randomized 2:1, RG7916:placebo) in patients with Type 2 or 3 SMA aged 2–25 years. SUNFISH comprises two parts: Part 1 is evaluating the safety, tolerability and PK/PD of several RG7916 dose levels (n=51); the pivotal Part 2 is assessing the safety and efficacy of the RG7916 dose level selected from Part 1 (n=168).

Results: We have previously presented an early analysis of SUNFISH Part 1, which showed that RG7916 administration results in a dose-dependent increase in full-length SMN2 mRNA and a concomitant decrease in SMN2Δ7 mRNA. Recent analysis of SMN protein levels in whole blood showed that in patients with SMA, SMN protein increased in a dose-dependent manner up to median 2.5-fold. The safety, tolerability and PK/PD data from Part 1 informed the selection of a RG7916 dose level for SUNFISH Part 2 predicted to lead to clinically efficacious increases in SMN protein. To date, no drug-related adverse events leading to withdrawal have been observed.

We will provide a detailed SUNFISH update with novel biomarker, PK and full unblinded safety results from Part 1.

Conclusions: In SUNFISH Part 1, RG7916 treatment modulated SMN2 mRNA and increased SMN protein dose-dependently. The clinical benefit of the selected dose level is being assessed in SUNFISH Part 2, which is currently recruiting globally.

Study Supported by:

F. Hoffmann-La Roche

Disclosure: Dr. Mercuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen MA, Inc, Ionis Pharmaceuticals, Inc. & F. Hoffman La-Roche Ltd. Dr. Baranello has nothing to disclose. Dr. Kirschner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Roche, Avexis. Dr. Kirschner has received research support from Biogen, Roche, Santhera, PTC. Dr. Servais has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Avexis, Sarepta, Dynacure, Pfizer, Servier. Dr. Servais has received research support from Roche, Valerion, Dynacure. Dr. Goemans has nothing to disclose. Dr. Pera has nothing to disclose. Dr. Marquet has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Armstrong has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Kletzl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Kletzl holds stock and/or stock options in Roche. Dr. Kletzl has received research support from Roche. Dr. Gerber has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Gerber holds stock and/or stock options in Roche. Dr. Czech has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd. Dr. Czech has received compensation for serving on the Board of Directors of F. Hoffmann-La Roche Ltd. Dr. Cleary has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F.Hoffmann-La Roche. Dr. Chan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Nave has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Gorni has nothing to disclose. Dr. Khwaja has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche. Dr. Khwaja holds stock and/or stock options in Roche, which sponsored research in which Dr. Khwaja was involved as an investigator. Dr. Khwaja has received research support from Roche.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (7)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise